我国肿瘤专科医院在数量和质量上都还不能完全满足患者需求,仍有为数众多的肿瘤患者不能得到专业、系统、有效的治疗。为了有效推进国内肿瘤医院的建设和发展,本报告以艾力彼医院管理研究中心发布的2020年中国肿瘤医院50强为研究对象,从综合情况、地理分布、竞争力要素等几个方面进行分析,以更好地展现中国肿瘤医院的医疗现状。结果显示,目前排前50名的大多是三级医院,说明目前国家已经在扶持和推进肿瘤医院的发展;从专业性来看,肿瘤专科医院竞争力比称为肿瘤医院的大专科小综合医院强;从规模和竞争能力上看,肿瘤专科医院的头部效应较为明显,形成了肿瘤医院发展的马太效应,这不利于分级诊疗和市场竞争。总体而言,目前国内肿瘤医院的发展还不能有效解决患者的就诊需求,国内肿瘤医院的发展依然显得迫切而必须。
<<The quantity and quality of oncology hospital can not satisfy the needs of patients,there are still a large number of oncology patients can not get professional,systematic and effective treatment. In order to promote the construction and development of domestic oncology hospital effectively,this paper analyzes the medical status of Chinese oncology hospital from the aspects of comprehensive situation,geographical distribution,competitive factors and so on. The results show that most of the top 50 hospitals are three-level and three-level hospitals,indicating that the country has begun to support and promote the development of the scale and strength of the specialized tumor hospitals;from the professional point of view,the competitiveness of the specialized tumor hospitals is stronger than that of the large specialized small comprehensive hospital known as the tumor hospitals;from the scale and competitiveness,the head effect of the specialized tumor hospitals is more obvious,forming the Matthew effect of the development of the cancer hospitals. This is not conducive to hierarchical diagnosis and treatment and market competition. In general,the development of domestic oncology hospital can not effectively solve the needs of patients,the development of domestic oncology hospital is still urgent and necessary.
<<